CD274 and melanoma: For example, TLR3 agonists have been shown to polarize macrophages toward an immune-activating phenotype in preclinical models of melanoma, and this increases the macrophage antigen presenting capabilities and decreases expression of PD-L1 and inhibitor receptors on infiltrating monocytes via the type 1 interferon signaling pathway [142].